Gan & Lee Pharmaceuticals

“The market for [biosimilar] adalimumab is not going to open up in a big way in calendar 2024, and the expectation is that it will happen in a more structured fashion in 2025,” said Biocon ’s group C

“The market for [biosimilar] adalimumab is not going to open up in a big way in calendar 2024, and the expectation is that it will happen in a more structured fashion in 2025,” said Biocon, Ltd. ’s g

Going into the third year of the global pandemic, residents of China's largest city are feeling uncertainty around potential extended lockdowns for the first time, the impact of which could affect a m

Going into the third year of the global pandemic, residents of China's largest city are feeling uncertainty around potential extended lockdowns for the first time, the impact of which could affect a m